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Abstract
Background: Methylated arginines are endogenous analogues of L-arginine, the substrate for nitric oxide (NO) synthase.
Asymmetric dimethylarginine (ADMA) interferes with NO formation, causing endothelial dysfunction. ADMA is a predictor of
cardiovascular events and mortality in humans. It is eliminated primarily by enzymatic activity of dimethylarginine
dimethylaminohydrolase (DDAH).
Methodology/Principal Findings: We investigated whether human DDAH-1 (hDDAH-1) transgenicity protects from
ischemic tissue damage in temporary middle cerebral artery occlusion (tMCAO) in mice. Infarct sizes did not significantly
differ between hDDAH-1 transgenic (TG) mice and wild-type littermates (WT). As expected, ADMA plasma concentrations
were significantly decreased, cerebral hDDAH expression and protein significantly increased in transgenic animals.
Interestingly, neither brain tissue DDAH activity nor ADMA concentrations were different between TG and WT mice. In
contrast, muscular DDAH activity was generally lower than in brain but significantly increased in TG mice.
Conclusion/Significance: Our study demonstrates that hDDAH-1 transgenic mice are not protected from ischemic cerebral
tissue damage in tMCAO. This lack of protection is due to high basal cerebral DDAH activity, which is not further increasable
by transgenic overexpression of DDAH.
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Introduction
Ischemic stroke is a devastating disease representing the second
leading cause of death in the western world and the leading cause
of disability in adults. Asymmetric dimethylarginine (ADMA) is an
inhibitor of nitric oxide (NO) synthesis and has been shown to be
associated with endothelial dysfunction (for review see [1]) whereas
symmetric dimethylarginine (SDMA) does not inhibit NO
synthases. Accordingly, ADMA impaired cerebral perfusion in
rats [2], and infusion of ADMA to healthy human subjects
increased arterial stiffness and decreased cerebral perfusion [3].
Elevated ADMA plasma levels are predictive for mortality and
future cardiovascular events in humans [4,5]. ADMA was also
reported to be a weak independent risk factor for stroke and TIA
[6] and is positively associated with internal carotid atherosclerosis
[7]. It is eliminated primarily by the enzymatic activity of
dimethylarginine dimethylaminohydrolase (DDAH) [8].
The aim of our study was to investigate whether mice
overexpressing an hDDAH-1 transgene and exhibiting decreased
plasma concentrations of ADMA [9], are protected from
experimental cerebral tissue damage due to ischemic stroke.
Methods
All animal experiments have been conducted according to
relevant national and international guidelines (German Animal
Welfare Act) and have been approved by the local Animal Care and
Use Committee (Beho ¨rde fu ¨r Soziales, Familie, Gesundheit und
Verbraucherschutz - Lebensmittelsicherheit und Veterina ¨rwesen -
26/07). Temporary middle cerebral artery occlusion (tMCAO) was
achieved as previously described (male TG and WT littermates, 20–
25 g, 10–12 weeks) [10]. Briefly, mice were anesthetized (isoflurane
1–2% v/v oxygen) and analgesized (buprenorphine 0.03 mg/kg
b.w. i.p. every 12 h for 24 h). tMCAO was achieved by using the
intraluminal filament method (6–0 nylon) for one hour. In the sham
group, arteries were visualized but not ligated. Exemplary mice
were monitored using transcranial temporal laser Doppler and
every mouse was scored on a scale from 0–5 (0 no deficit, 1
preferential turning, 2 circling, 3 longitudinal rolling, 4 no
movement, 5 death) after reawakening and every day until sacrifice.
Mice were sacrificed 2 days after reperfusion using isoflurane and
decapitation. Blood samples were obtained at time of sacrifice. Only
mice with a score greater or equal than one after reawakening were
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included. Brains were harvested, cut into 1 mm standardized slices
(Braintree Scientific, 1 mm) and vital stained using 2% (w/v) 2,3,5-
triphenyl-2H-tetrazolium chloride (TTC) in phosphate buffer.
Slices were scanned on a flat bed scanner, infarct volume
determined by blinded examiners using NIH ImageJ. Infarcts were
categorized as strictly striatal or territorial (striatal plus cortical) and
analyzed separately. Edema corrected infarct size was calculated
(Volume Infarct*Volume contralesional hemisphere/Volume ipsi-
lesional hemisphere) and statistics (two-sided T-test, Graph Pad
Prism) performed. For india ink vascular staining, WT and TG
animals were anesthetized (isoflurane) and perfused with PBS
followed by4%paraformaldehyde andindiaink(50%indiaink,5%
gelatine in PBS). After refrigerating (4uC) overnight, mice were
dissected under a binocular microscope and visualized using a
digital camera (Dino Lite Pro).
Western blots were performed according to standard protocols
(rabbit polyclonal antibodies against DDAH1 (Eurogentec, Ko ¨ln,
Gemany) and against b-tubulin (Abcam, Cambridge, MA).
Circulating plasma levels of ADMA, SDMA, and L-arginine were
determined using a validated high-throughput liquid chromatog-
raphy - tandem mass spectrometry (LC-MS/MS) assay. DDAH
activity was quantified in brain and skeletal muscle homogenates
by measuring the degradation of [
2H6]-ADMA (n=6–8) [11].
Real time PCR was performed from brain tissue (WT n=8, TG
n=7) according to manufacturers’ protocols using standard
conditions (7900 Fast system, Applied Biosystems, Darmstadt,
Germany, Hs00201707 m1 for hDDAH1, Mm01319453 m1 for
DDAH1, and Mm00516768 m1 for DDAH2). Significance was
tested by two-sided T-test (Graph Pad Prism).
Results
The analysis was 80% powered to see a 20% reduction in
infarct size. Direct effects of genotype on development of
vasculature could severely bias our ischemia model and needed
Figure 1. A Cerebral vascular anatomy is not influenced by genotype. Representative cerebral vasculature india ink staining in WT and TG mice. *
Branching of internal carotidartery, white dash: partiallyhiddenlocation ofanastomosisof internal carotid andbasilarterritories. Lessintense stainingof
vessels in the depicted WT animal is due to small differences in india ink perfusion pressure. No systematic difference in vascular architecture was
observed (WT n=4, TG n=4). B Transtemporal laser doppler analysis of relative cortical blood flow dynamics after insertion of filament shows no
difference between WT and TG mice. Baseline was defined as pre-ischemia cerebral blood flow and defined as 100%. WT n=3, TG n=3.
doi:10.1371/journal.pone.0007337.g001
Figure 2. hDDAH-1 transgenic mice are not protected from experimental stroke. A Representative vital staining (TTC) of WT and TG mice
brain sections B Infarcted area in mm
3 (edema corrected, WT n=14, TG n=11, striatal WT n=6 TG n=5, territorial WT n=8 TG n=6). Error bars
represent standard deviation. N.s. not significant.
doi:10.1371/journal.pone.0007337.g002
DDAH1 Overexpression in tMCAO
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7337to be ruled out. We neither found differences in vascular anatomy
nor blood flow reduction/reperfusion between TG and WT
animals (Figure 1). However, we did not observe significantly
different infarct sizes in our model. Edema corrected infarct sizes
were in WT 43 mm
3 (n=13, 95% CI 24–61) and in TG 37 mm
3
(n=11, 95% CI 17–57) (p=0.49, Fig. 2). Because striatal infarcts
were slightly more common in WT animals (6/8) than in TG mice
(5/8), we analyzed striatal and territorial infarcts separately. This
also did not lead to significant differences. Infarct sizes were
19 mm
3 (n=6, 95% CI 11–27) for striatal and 61 mm
3 (n=8, CI
54–68) for territorial infarcts in WT mice versus 13 mm
3 (n=5, CI
6–20) for striatal and 59 mm
3 (n=6, CI 47–67) for territorial
infarcts in TG animals (p=0.27 for striatal and p=0.53 for
territorial infarcts) (Fig. 2).
To explain the lack of protection, we examined ADMA levels as
well as expression and enzymatic activity of endogenous and
transgenic DDAH. As expected, circulating ADMA plasma
concentration was decreased by 40% in TG animals as compared
to WT (p,0.01, Table 1). For SDMA and L-arginine, no
significant differences were seen (Table 1). The L-arginine:ADMA
ratio was significantly higher in TG mice due to lower ADMA
levels, while the L-arginine:SDMA ratio did not differ significantly
(Table 1). Endogenous cerebral murine DDAH-1 and -2 mRNA
expression was not significantly different, while transgenic human
hDDAH-1 mRNA levels in brain were only detectable in TG mice
(Fig. 3A). Accordingly, DDAH-1 protein was increased in cerebral
tissue of TG mice (Fig. 3B).
Surprisingly, in spite of increased transcription and translation
of transgenic protein in the brain, we did not find a significant
difference in brain DDAH activity (WT 8.560.8 vs. TG,
7.961.0 nmol/g protein/min; Fig. 3C) or cerebral tissue ADMA
levels (WT 19.162.2 vs. TG, 14.862.0 nmol/g protein; Fig. 3D)
between transgenic animals and littermates. In contrast in muscle
tissue, muscular DDAH activity was significantly increased in TG
animals (WT 0.860.1 vs. TG, 2.360.4 nmol/g protein/min;
Fig. 3C). However, littermate and transgenic DDAH activities of
skeletal muscle were only 10% and 30% of brain DDAH activity,
respectively.
Discussion
Previously, higher vasomotor capacities in medium- to small-
sized arteries and improved perfusion in hDDAH-1 transgenic
mice were demonstrated [2,9]. However, in our study we observed
no effect of transgenicity on cerebral infarct size. As the human b-
actin promoter was used to construct the transgene [12],
ubiquitous expression of mRNA and enhanced DDAH activity
in large arteries was anticipated. In accordance with this, we found
expression of hDDAH-1 both on the mRNA and protein level in
brains of TG mice. Nevertheless, we show here that DDAH
activity in the brain of TG mice was not different from WT
animals and concomitantly cerebral ADMA tissue levels remained
unchanged.
Interestingly, in organs where elevated DDAH activity had been
found in transgenic mice [12,13] protection from ischemia was
noticeable. For example, in models of hind limb and myocardial
ischemia increased angiogenesis and reduced damage were
observed [14,15]. Fittingly, we showed increased muscular DDAH
activity in transgenic animals but with a much lower activity level
compared to the brain. With regard to the transgenic model it
seems that no further increase in DDAH activity can be achieved
in the brain explaining our observed lack of protection from
stroke.
Figure 3. Cerebral DDAH activity is not increased in hDDAH-1
transgenic mice despite a significant difference in hDDAH-1
expression and translation. Muscular DDAH activity is increased but
generally lower than cerebral DDAH activity. A Quantitative PCR.
Relative expression in TG vs. WT mice. (n=7–8) B Western blot, brain
homogenate. Beta-tubulin and DDAH-1 antibodies (n=3) C Cerebral
and muscular DDAH activity. Brain and muscle homogenate (n=6–8) D
ADMA concentration. Brain homogenate (n=6–8). Error bars represent
standard deviation. WT wildtype; TG hDDAH-1 transgenic animals, n.s.
not significant, ** p,0.01.
doi:10.1371/journal.pone.0007337.g003
Table 1. Mean plasma levels with 95% confidence intervalls
in brackets.
WT TG p
ADMA mmol/l 0.72 (0.60–0.83) 0.43 (0.34–0.53) ,0.01
SDMA mmol/l 0.18 (0.16–0.21) 0.17 (0.12–0.23) 0.73
L-Arginine mmol/l 72.7 (50.2–95.1) 95.0 (61.6–128.5) 0.30
Arg:ADMA 104.1 (76.5–131.6) 231.3 (166.0–296.5) ,0.01
Arg:SDMA 403.5 (290.7–516.3) 662.0 (451.2–872.8) 0.05
Statistics by two-sided T-test.
doi:10.1371/journal.pone.0007337.t001
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from endothelial dysfunction in cerebral arterioles [9]. Therefore,
local endothelial effects of increased DDAH-expression have been
postulated. The lack of a protective effect of the DDAH-1
transgene in our model with significantly different ADMA plasma
levels points to a minor relevance of these observations for infarct
size. Correspondingly, epidemiologic data shows ADMA to be
only a minor risk factor for stroke in humans [6]. Currently, the
influence of DDAH transgenicity on non-vascular, rather than
vascular mechanisms contributing to secondary cerebral damage
can not be answered. Further work to elucidate non-vascular
effects of DDAH-1 is needed.
In summary, our findings suggest that hDDAH-1 overexpres-
sion and concurrent reduction in plasma ADMA concentrations
do not change the outcome of stroke. This is likely due to the
inability of the transgene to further increase already high
background activity of DDAH in the brain.
Author Contributions
Conceived and designed the experiments: FL CUC MG ES CG KS RHB
TM. Performed the experiments: FL CUC MG ECvL DA. Analyzed the
data: FL CUC MG ECvL DA ES CG KS RHB TM. Contributed
reagents/materials/analysis tools: FL TM. Wrote the paper: FL CUC MG
ECvL DA ES CG KS RHB TM.
References
1. Bo ¨ger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in
cardiovascular medicine and beyond. Ann Med 38: 126–136.
2. Faraci FM, Brian JE Jr, Heistad DD (1995) Response of cerebral blood vessels to
an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269:
H1522–1527.
3. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, et al. (2006) ADMA
increases arterial stiffness and decreases cerebral blood flow in humans. Stroke
37: 2024–2029.
4. Maas R, Schulze F, Baumert J, Lo ¨wel H, Hamraz K, et al. (2007) Asymmetric
dimethylarginine, smoking, and risk of coronary heart disease in apparently
healthy men: prospective analysis from the population-based Monitoring of
Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheits-
forschung in der Region Augsburg study and experimental data. Clin Chem 53:
693–701.
5. Bo ¨ger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, et al. (2009) Plasma
asymmetric dimethylarginine and incidence of cardiovascular disease and death
in the community. Circulation 119(12): 1592–1600.
6. Wanby P, Teerlink T, Brudin L, Brattstro ¨m L, Nilsson I, et al. (2006)
Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a
Swedish population. Atherosclerosis 185: 271–277.
7. Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, et al. (2009)
Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA With
Carotid Artery Intimal Media Thickness in the Framingham Heart Study
Offspring Cohort. Stroke Epub ahead of print.
8. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003)
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in
humans and is actively metabolized by dimethylarginine dimethylaminohydro-
lase. Arterioscler Thromb Vasc Biol 23: 1455–1459.
9. Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, et al. (2008)
Overexpression of Dimethylarginine Dimethylaminohydrolase Inhibits Asym-
metric Dimethylarginine–Induce Endothelial Dysfunction in the Cerebral
Circulation. Stroke 39: 180–184.
10. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, et al. (2009)
Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.
Stroke 40(5): 1849–1857.
11. Konishi H, Sydow K, Cooke JP (2007) Dimethylarginine dimethylaminohy-
drolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 49:
1099–1105.
12. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, et al. (2003)
Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis:
genetic and physiological evidence. Circulation 108: 3042–3047.
13. Maas R, Tan-Andreesen J, Schwedhelm E, Schulze F, Bo ¨ger RH (2007) A
stable-isotope based technique for the determination of dimethylarginine
dimethylaminohydrolase (DDAH) activity in mouse tissue.
J Chromatogr B Analyt Technol Biomed Life Sci 851: 220–228.
14. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, et al. (2005)
Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue
asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 111:
1431–1438.
15. Stu ¨hlinger MC, Conci E, Haubner BJ, Stocker EM, Schwaighofer J et al (2007)
Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial
reperfusion injury. Cardiovasc Res 75: 417–425.
DDAH1 Overexpression in tMCAO
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7337